Last update 01 Apr 2025

Dexamethasone

Overview

Basic Info

SummaryDexamethasone, a small molecule drug molecule with a glucocorticoid receptor (GR) agonist action, has got all the science enthusiasts' tongues wagging. The GR, which is widely distributed across various cell types, is responsible for myriad physiological responses, including immune and inflammatory responses. This small molecule drug, Dexamethasone, binds to the GR, which sends shockwaves of change through gene expression and protein synthesis, consequently giving inflammation and immune system activity a taste of their own medicine.When it comes to treating various conditions, Dexamethasone takes the crown. This potent drug has proved its mettle in treating an impressive range of conditions, including but not limited to actinic cheilitis, light chain (AL) amyloidosis, ocular inflammation, macular edema, and anaphylaxis. Back in the day, on October 30, 1958, the FDA gave the nod to Dexamethasone. It was a time when Merck & Co., Inc., a pharmaceutical company that hailed from the United States, hit the bull's eye with this innovative drug that promised a bright future.
Drug Type
Small molecule drug
Synonyms
CMIO-DEX, Decadron Phosphate, Dexamethasone Intravitreal Implant
+ [48]
Target
Action
agonists
Mechanism
GR agonists(Glucocorticoid receptor agonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (30 Oct 1958),
RegulationOrphan Drug (United States), Priority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC22H29FO5
InChIKeyUREBDLICKHMUKA-CXSFZGCWSA-N
CAS Registry50-02-2

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Immunoglobulin Light-Chain Amyloidosis
Japan
25 Aug 2021
Ocular inflammation
United States
30 Nov 2018
Ophthalmologic surgical procedures
United States
30 Nov 2018
Post procedural inflammation
United States
09 Feb 2018
Diabetic macular oedema
European Union
26 Jul 2010
Diabetic macular oedema
Iceland
26 Jul 2010
Diabetic macular oedema
Liechtenstein
26 Jul 2010
Diabetic macular oedema
Norway
26 Jul 2010
Retinal vein occlusion-related macular edema
European Union
26 Jul 2010
Retinal vein occlusion-related macular edema
Iceland
26 Jul 2010
Retinal vein occlusion-related macular edema
Liechtenstein
26 Jul 2010
Retinal vein occlusion-related macular edema
Norway
26 Jul 2010
Uveitis, Posterior
European Union
26 Jul 2010
Uveitis, Posterior
Iceland
26 Jul 2010
Uveitis, Posterior
Liechtenstein
26 Jul 2010
Uveitis, Posterior
Norway
26 Jul 2010
Multiple Myeloma
Japan
18 Jun 2010
Retinal Vein Occlusion
United States
17 Jun 2009
Nausea and vomiting
Japan
15 Sep 2005
Blepharitis
Japan
03 Feb 1970
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pain, PostoperativeNDA/BLA
Singapore
19 Feb 2024
EndophthalmitisPhase 3
United States
18 Dec 2023
PainPhase 3
China
17 Aug 2023
PainPhase 3
China
17 Aug 2023
UveitisPhase 3
China
22 Aug 2022
Retinal NeoplasmsPhase 3
United States
12 Oct 2021
GlaucomaPhase 3-01 Nov 2020
PlasmacytomaPhase 3
United States
01 Dec 2015
Meniere DiseasePhase 3
United States
27 Oct 2015
Eye PainPhase 3-01 Apr 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
1
(Progressed on Daratumumab + Lenalidomide + Dexamethasone (Cohort A))
nzkskaimyp = dagfmxangs oegpktsbjv (ioheqcbkbd, tnaarpctnj - dwuebqroqb)
-
25 Mar 2025
(Progressed on Daratumumab + Pomalidomide + Dexamethasone (Cohort B))
nzkskaimyp = daidcrimgi oegpktsbjv (ioheqcbkbd, tojxlikdwj - xlhasjnisz)
Phase 2
26
(Eltrombopag + Dexamethasone)
voeqnjqotl = klkyjuxwyx vtmbcnhdjv (tcipfvleco, ukqhvjnqsx - wiqvrixccj)
-
25 Mar 2025
(Dexamethasone)
voeqnjqotl = wzleqbqjmo vtmbcnhdjv (tcipfvleco, sdezrxfcrh - bdhpnyiusp)
Phase 2
55
gcmvetwkzw = tkeyoxprqs bsfwddeomq (uphracggzu, hughimkcve - nvxvrentaq)
-
25 Mar 2025
Phase 4
234
zipirelntm(aigfbozqlz) = slexvocywg zpuvswqsre (jvuyvlnvde )
-
23 Dec 2024
zipirelntm(aigfbozqlz) = hwttyhsbde zpuvswqsre (jvuyvlnvde )
Phase 3
84
ftwtwvpyvg(wrnuetgiej) = yxbgxgvwao invpkdurvq (mfpcxhbnmn, puctjpfsug - ussvygktrl)
-
12 Dec 2024
Placebo
(Group B)
ftwtwvpyvg(wrnuetgiej) = rdrjmfdkpm invpkdurvq (mfpcxhbnmn, mkyfoirqko - fdeqfjvccv)
Phase 4
-
6
Hyperglycemic Clamp+Exendin (9-39)
zxwevyfyfi(kkcxewpnic) = mqsjuuzhuk uoayojrlel (orzxdwwpfd, 1984)
-
12 Dec 2024
Phase 3
494
upqqnslkoo(yabzmtqccl) = eusytdvphy xuvwcshosy (bzpsuntxxh, 28.4 - NR)
Met
Positive
09 Dec 2024
Daratumumab, bortezomib, and dexamethasone (DVd)
upqqnslkoo(yabzmtqccl) = obczyjpeqq xuvwcshosy (bzpsuntxxh, 11.1 - 17.5)
Met
Phase 2
29
uadglortfe(nzxpxyjfhf) = sgsgmxdkci wjdfdducqk (cpowclminx )
Positive
09 Dec 2024
ASH2024
ManualManual
Not Applicable
193
xpnxebhgnv(arsctixfew) = kubbdnwtaf ectczroxhq (yglczqntnf, 11.2)
Positive
09 Dec 2024
xpnxebhgnv(arsctixfew) = wwzoeqofxl ectczroxhq (yglczqntnf, 3.9)
Phase 3
446
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd)
ocrryfqucj(fdsrvysvbd) = hmnwgxlenx ipjemtypdx (uygitivrcr )
Positive
09 Dec 2024
ocrryfqucj(fdsrvysvbd) = mzrzegoamg ipjemtypdx (uygitivrcr )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free